JDRF T1D Fund
VC Fund
Boston, United States
JDRF T1D Fund is a VC fund in Boston focused on Biotechnology and Health Care. The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
- Total investments:
- 55
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries JDRF T1D Fund invests in
Stages JDRF T1D Fund invests in
Countries JDRF T1D Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $7M–$105M
- Series B
- $18M–$130M
Investment Focus
Industry
- Biotechnology 34 (62%)
- Health Care 22 (40%)
- Medical 14 (25%)
- Therapeutics 14 (25%)
- Life Science 11 (20%)
Stage
- Series A 16 (29%)
- Series B 10 (18%)
- Funding Round 7 (13%)
- Seed 5 (9%)
- Series C 4 (7%)
Country
- United States 29 (53%)
- Canada 3 (5%)
- France 2 (4%)
- Italy 1 (2%)
- Israel 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brian Malik
Investment Professional
|
Investment Professional | Total investments: 0 | Find email | |
Jerry Wisler
Member, Investment Committee
|
Member, Investment Committee | Total investments: 0 | Find email | |
Jonathan Behr
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Jonathan Behr
Managing Director
|
Managing Director | Total investments: 9 | Find email | |
Katie Ellias
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Zag Bio
|
Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M / Series A / Oct 28, 2025 | |
vTv Therapeutics
|
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing. | $80M / Post-IPO Equity / Sep 02, 2025 | |
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $320.8M / Series D / Aug 15, 2025 | |
SAB Biotherapeutics
|
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats. | $175M / Post-IPO Equity / Jul 21, 2025 | |
Zucara Therapeutics
|
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically blocksomatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar. | $5M / Series B / May 01, 2025 | |
Aspect Biosystems
|
Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $115M / Series B / Jan 08, 2025 | |
Eledon Pharmaceuticals
|
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. | $85M / Post-IPO Equity / Oct 29, 2024 | |
|
vTv Therapeutics
|
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing. | $51M / Post-IPO Equity / Feb 27, 2024 | |
Cour Pharmaceuticals Development
|
Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $105M / Series A / Jan 30, 2024 | |
|
SAB Biotherapeutics
|
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats. | $130M / Post-IPO Equity / Oct 02, 2023 | |
| See all 55 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does JDRF T1D Fund invest in?
JDRF T1D Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 55 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is JDRF T1D Fund's check size?
JDRF T1D Fund typically joins rounds of $7M–$105M at Series A and $18M–$130M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds JDRF T1D Fund participates in.
How do I contact JDRF T1D Fund?
Public channels for JDRF T1D Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at JDRF T1D Fund?
The team at JDRF T1D Fund includes Brian Malik (Investment Professional), Jerry Wisler (Member, Investment Committee) and Jonathan Behr (Managing Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
